Prestige Consumer Healthcare Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 2, 2023 and accepted by EDGAR at Nov 2, 2023, 06:11 ET.
Management's discussion and analysis
As filed, 34,454 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion of our financial condition and results of operations should be read together with the Condensed Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 and in future reports filed with the U.S. Securities and Exchange Commission ("SEC").
See also “Cautionary Statement Regarding Forward-Looking Statements” on page 30 of this Quarterly Report on Form 10-Q.
Unless otherwise indicated by the context, all references in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Similarly, references to a year (e.g., 2024) refers to our fiscal year ended March 31 of that year.
General
We are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter ("OTC") healthcare products to mass merchandisers, drug, food, dollar, convenience, and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage.
We have grown our brand portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of OTC brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies and private equity firms. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a core brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network. We pursue this growth through increased spending on advertising and marketing support, new sales and marketing strategies, improved packaging and formulations, and innovative development of brand extensions.
Economic Environment
There has been economic uncertainty in the United States and globally due to several factors, including global supply chain constraints, rising interest rates, a high inflationary environment and geopolitical events. We expect economic conditions will continue to be highly volatile and uncertain, put pressure on prices and supply, and could affect demand for our products. We have continued to see changes in the purchasing patterns of our consumers, including a reduction in the frequency of visits to retailers and a shift in many markets to purchasing our products online.
The volatile environment has impacted the supply of labor and raw materials and exacerbated rising input costs. Although we have not experienced a material disruption to our overall supply chain to date, we have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs. In addition, labor shortages have impacted our manufacturing operations and may impact our ability to supply certain products to our customers. To date, these global conditions have not had a material negative impact on our operations, supply chain, overall costs or demand for most of our products or resulting aggregate sales and earnings, and, as such, it has also not materially negatively impacted our liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs. These circumstances could change, however, in this dynamic environment. If conditions cause further disruption in the global supply chain, the availability of labor and materials or otherwise further increase costs, it may materially affect our operations and those of third parties on which we rely, including causing material disruptions in the supply and distribution of our products. The extent to which these conditions impact our results and liquidity will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning global supply chain constraints, the high inflationary environment, global instability and the potential for further outbreaks of severe illnesses. These effects could have a material adverse impact on our business, liquidity, capital resources, and results of operations and those of the third parties on which we rely.
-21-
Results of Operations
Three Months Ended September 30, 2023 compared to the Three Months Ended September 30, 2022
Total Segment Revenues
The following table represents total revenue by segment, including product groups, for the three months ended September 30, 2023 and 2022.
| Three Months Ended September 30, | Increase (Decrease) | ||
|---|---|---|---|
| (In thousands) | 2023% | 2022% | Amount% |
| North American OTC Healthcare | |||
| Analgesics | $29,976 10.5 | $32,750 11.3 | $(2,774) (8.5) |
| Cough & Cold | 25,970 9.1 | 24,058 8.3 | 1,912 7.9 |
| Women's Health | 55,000 19.3 | 59,379 20.5 | (4,379) (7.4) |
| Gastrointestinal | 38,703 13.5 | 41,272 14.3 | (2,569) (6.2) |
| Eye & Ear Care | 39,745 13.9 | 37,961 13.1 | 1,784 4.7 |
| Dermatologicals | 33,018 11.5 | 32,872 11.4 | 146 0.4 |
| Oral Care | 19,312 6.7 | 21,251 7.3 | (1,939) (9.1) |
| Other OTC | 2,699 0.9 | 2,511 0.9 | 188 7.5 |
| Total North American OTC Healthcare | 244,423 85.4 | 252,054 87.1 | (7,631) (3.0) |
| International OTC Healthcare | |||
| Analgesics | $1,386 0.5 | $541 0.2 | 845 156.2 |
| Cough & Cold | 7,263 2.5 | 7,168 2.5 | 95 1.3 |
| Women's Health | 7,072 2.5 | 4,745 1.6 | 2,327 49.0 |
| Gastrointestinal | 14,061 4.9 | 16,037 5.5 | (1,976) (12.3) |
| Eye & Ear Care | 7,125 2.5 | 4,734 1.7 | 2,391 50.5 |
| Dermatologicals | 1,469 0.5 | 902 0.3 | 567 62.9 |
| Oral Care | 3,469 1.2 | 3,080 1.1 | 389 12.6 |
| Other OTC | 48 — | 12 — | 36 300.0 |
| Total International OTC Healthcare | 41,893 14.6 | 37,219 12.9 | 4,674 12.6 |
| Total Consolidated | $286,316 100.0 | $289,273 100.0 | $(2,957) (1.0) |
Total revenues for the three months ended September 30, 2023 were $286.3 million, a decrease of $3.0 million, or 1.0%, versus the three months ended September 30, 2022.
North American OTC Healthcare Segment
Revenues for the North American OTC Healthcare segment decreased $7.6 million, or 3.0%, during the three months ended September 30, 2023 versus the three months ended September 30, 2022. The $7.6 million decrease was primarily attributable to a decline in sales in the Women's Health and certain other categories, partly offset by an increase in sales in the Cough & Cold and Eye & Ear categories.
International OTC Healthcare Segment
Revenues for the International OTC Healthcare segment increased $4.7 million, or 12.6%, during the three months ended September 30, 2023 versus the three months ended September 30, 2022. The $4.7 million increase was primarily attributable to an increase in sales in the Eye & Ear Care and Women's Health categories, partly offset by a decrease in sales in the Gastrointestinal category.
-22-
Gross Profit
The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.
(In thousands)
| Three Months Ended September 30, | Increase (Decrease) | ||
|---|---|---|---|
| Gross Profit | 2023% | 2022% | Amount% |
| North American OTC Healthcare | $136,957 56.0 | $138,521 55.0 | $(1,564) (1.1) |
| International OTC Healthcare | 23,063 55.1 | 22,488 60.4 | 575 2.6 |
| $160,020 55.9 | $161,009 55.7 | $(989) (0.6) |
Gross profit for the three months ended September 30, 2023 decreased $1.0 million, or 0.6%, when compared with the three months ended September 30, 2022. As a percentage of total revenues, gross profit increased to 55.9% during the three months ended September 30, 2023, from 55.7% during the three months ended September 30, 2022, primarily due to reduced logistics costs in our North American OTC Healthcare segment.
North American OTC Healthcare Segment
Gross profit for the North American OTC Healthcare segment decreased $1.6 million, or 1.1%, during the three months ended September 30, 2023 versus the three months ended September 30, 2022. As a percentage of North American OTC Healthcare revenues, gross profit increased to 56.0% during the three months ended September 30, 2023 from 55.0% during the three months ended September 30, 2022, primarily due to reduced logistics costs.
International OTC Healthcare Segment
Gross profit for the International OTC Healthcare segment increased $0.6 million, or 2.6%, during the three months ended September 30, 2023 versus the three months ended September 30, 2022. As a percentage of International OTC Healthcare revenues, gross profit decreased to 55.1% during the three months ended September 30, 2023 from 60.4% during the three months ended September 30, 2022, primarily due to increased supply chain costs and product mix.
Contribution Margin
Contribution margin is our segment measure of profitability. It is defined as gross profit less advertising and marketing expenses.
The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.
(In thousands)
| Three Months Ended September 30, | Increase (Decrease) | ||
|---|---|---|---|
| Contribution Margin | 2023% | 2022% | Amount% |
| North American OTC Healthcare | $101,568 41.6 | $99,205 39.4 | $2,363 2.4 |
| International OTC Healthcare | 18,350 43.8 | 17,985 48.3 | 365 2.0 |
| $119,918 41.9 | $117,190 40.5 | $2,728 2.3 |
North American OTC Healthcare Segment
Contribution margin for the North American OTC Healthcare segment increased $2.4 million, or 2.4%, during the three months ended September 30, 2023 versus the three months ended September 30, 2022. As a percentage of North American OTC Healthcare revenues, contribution margin increased to 41.6% during the three months ended September 30, 2023 from 39.4% during the three months ended September 30, 2022. The contribution margin increase as a percentage of revenues was primarily due to a decrease in advertising and marketing spend in the three months ended September 30, 2023, as well as the increase in gross profit margin noted above.
International OTC Healthcare Segment
Contribution margin for the International OTC Healthcare segment increased $0.4 million, or 2.0%, during the three months ended September 30, 2023 versus the three months ended September 30, 2022. As a percentage of International OTC Healthcare revenues, contribution margin decreased to 43.8% during the three months ended September 30, 2023 from 48.3% during the three months ended September 30, 2022. The contribution margin decrease as a percentage of revenues was primarily due to the decrease in gross profit margin noted above.
-23-
General and Administrative
General and administrative expenses were $26.0 million for the three months ended September 30, 2023 and $26.4 million for the three months ended September 30, 2022.
Depreciation and Amortization
Depreciation and amortization expenses decreased to $5.7 million for the three months ended September 30, 2023 from $6.4 million for the three months ended September 30, 2022. The decrease in depreciation and amortization expenses was primarily attributable to a decrease in amortization expense due to impairment charges taken on finite-lived brands in fiscal 2023.
Interest Expense, Net
Interest expense, net was $17.6 million during the three months ended September 30, 2023 versus $17.0 million during the three months ended September 30, 2022. The average indebtedness decreased to $1.3 billion during the three months ended September 30, 2023 from $1.5 billion during the three months ended September 30, 2022. The average cost of borrowing increased to 5.5% for the three months ended September 30, 2023 from 4.6% for the three months ended September 30, 2022.
Income Taxes
The provision for income taxes during the three months ended September 30, 2023 was $16.9 million versus $15.6 million during the three months ended September 30, 2022. The effective tax rate during the three months ended September 30, 2023 was 23.9% versus 23.4% during the three months ended September 30, 2022. The increase in the effective tax rate for the three months ended September 30, 2023 was due to the impact of discrete items primarily pertaining to stock-based compensation.
-24-
Results of Operations
Six Months Ended September 30, 2023 compared to the Six Months Ended September 30, 2022
Total Segment Revenues
The following table represents total revenue by segment, including product groups, for the six months ended September 30, 2023 and 2022.
| Six Months Ended September 30, | Increase (Decrease) | ||
|---|---|---|---|
| (In thousands) | 2023% | 2022% | Amount% |
| North American OTC Healthcare | |||
| Analgesics | $57,158 10.1 | $60,547 10.7 | $(3,389) (5.6) |
| Cough & Cold | 46,344 8.2 | 45,650 8.1 | 694 1.5 |
| Women's Health | 109,955 19.4 | 120,563 21.3 | (10,608) (8.8) |
| Gastrointestinal | 83,384 14.7 | 81,339 14.4 | 2,045 2.5 |
| Eye & Ear Care | 79,216 14.0 | 76,572 13.4 | 2,644 3.5 |
| Dermatologicals | 67,696 12.0 | 62,327 11.0 | 5,369 8.6 |
| Oral Care | 41,038 7.3 | 42,226 7.5 | (1,188) (2.8) |
| Other OTC | 5,775 1.0 | 5,348 0.9 | 427 8.0 |
| Total North American OTC Healthcare | 490,566 86.7 | 494,572 87.3 | (4,006) (0.8) |
| International OTC Healthcare | |||
| Analgesics | 2,228 0.4 | 994 0.2 | 1,234 124.1 |
| Cough & Cold | 13,315 2.4 | 13,439 2.3 | (124) (0.9) |
| Women's Health | 12,028 2.1 | 9,612 1.8 | 2,416 25.1 |
| Gastrointestinal | 26,971 4.8 | 30,064 5.3 | (3,093) (10.3) |
| Eye & Ear Care | 11,146 2.0 | 9,470 1.7 | 1,676 17.7 |
| Dermatologicals | 2,807 0.5 | 1,908 0.3 | 899 47.1 |
| Oral Care | 6,491 1.1 | 6,250 1.1 | 241 3.9 |
| Other OTC | 73 — | 23 — | 50 217.4 |
| Total International OTC Healthcare | 75,059 13.3 | 71,760 12.7 | 3,299 4.6 |
| Total Consolidated | $565,625 100.0 | $566,332 100.0 | $(707) (0.1) |
Total revenues for the six months ended September 30, 2023 were $565.6 million, a decrease of $0.7 million, or 0.1%, versus the six months ended September 30, 2022.
North American OTC Healthcare Segment
Revenues for the North American OTC Healthcare segment decreased $4.0 million, or 0.8%, during the six months ended September 30, 2023 versus the six months ended September 30, 2022. The $4.0 million decrease was primarily attributable to a decrease in sales in the Women's Health and Analgesics categories, partly offset by an increase in sales in the Dermatologicals, Eye & Ear Care and Gastrointestinal categories.
International OTC Healthcare Segment
Revenues for the International OTC Healthcare segment increased $3.3 million, or 4.6%, during the six months ended September 30, 2023 versus the six months ended September 30, 2022. The $3.3 million increase was mainly attributable to an increase in sales in the Women's Health, Eye & Ear Care and Analgesics categories, partly offset by a decrease in sales in the Gastrointestinal category.
-25-
Gross Profit
The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.
(In thousands)
| Six Months Ended September 30, | Increase (Decrease) | ||
|---|---|---|---|
| Gross Profit | 2023% | 2022% | Amount% |
| North American OTC Healthcare | $273,024 55.7 | $278,118 56.2 | $(5,094) (1.8) |
| International OTC Healthcare | 41,669 55.5 | 43,010 59.9 | (1,341) (3.1) |
| $314,693 55.6 | $321,128 56.7 | $(6,435) (2.0) |
Gross profit for the six months ended September 30, 2023 decreased $6.4 million, or 2.0%, when compared with the six months ended September 30, 2022. As a percentage of total revenues, gross profit decreased to 55.6% during the six months ended September 30, 2023, from 56.7% during the six months ended September 30, 2022, primarily due to increased supply chain costs and product mix, partly offset by pricing actions.
North American OTC Healthcare Segment
Gross profit for the North American OTC Healthcare segment decreased $5.1 million, or 1.8%, during the six months ended September 30, 2023 versus the six months ended September 30, 2022. As a percentage of North American OTC Healthcare revenues, gross profit decreased to 55.7% during the six months ended September 30, 2023 from 56.2% during the six months ended September 30, 2022, primarily due to increased supply chain costs, partly offset by product mix and pricing actions.
International OTC Healthcare Segment
Gross profit for the International OTC Healthcare segment decreased $1.3 million, or 3.1%, during the six months ended September 30, 2023 versus the six months ended September 30, 2022. As a percentage of International OTC Healthcare revenues, gross profit decreased to 55.5% during the six months ended September 30, 2023 from 59.9% during the six months ended September 30, 2022, primarily due to increased supply chain costs and product mix.
Contribution Margin
Contribution margin is our segment measure of profitability. It is defined as gross profit less advertising and marketing expenses.
The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.
(In thousands)
| Six Months Ended September 30, | Increase (Decrease) | ||
|---|---|---|---|
| Contribution Margin | 2023% | 2022% | Amount% |
| North American OTC Healthcare | $206,234 42.0 | $203,390 41.1 | $2,844 1.4 |
| International OTC Healthcare | 32,126 42.8 | 33,968 47.3 | (1,842) (5.4) |
| $238,360 42.1 | $237,358 41.9 | $1,002 0.4 |
North American OTC Healthcare Segment
Contribution margin for the North American OTC Healthcare segment for the six months ended September 30, 2023 increased $2.8 million, or 1.4%, when compared with the six months ended September 30, 2022. As a percentage of North American OTC Healthcare revenues, contribution margin increased to 42.0% during the six months ended September 30, 2023 from 41.1% during the six months ended September 30, 2022, primarily due to a decrease in advertising and marketing spend in the six months ended September 30, 2023.
International OTC Healthcare Segment
Contribution margin for the International OTC Healthcare segment decreased $1.8 million, or 5.4%, during the six months ended September 30, 2023 versus the six months ended September 30, 2022. As a percentage of International OTC Healthcare revenues, contribution margin decreased to 42.8% during the six months ended September 30, 2023 from 47.3% during the six months ended September 30, 2022. The contribution margin decrease as a percentage of revenues was primarily due to the decrease in gross profit margin noted above.
-26-
General and Administrative
General and administrative expenses were $53.7 million for the six months ended September 30, 2023 and $53.2 million for the six months ended September 30, 2022.
Depreciation and Amortization
Depreciation and amortization expenses were $11.2 million for the six months ended September 30, 2023 and $12.8 million for the six months ended September 30, 2022. The decrease in depreciation and amortization expenses was primarily attributable to a decrease in amortization expense due to impairment charges taken on finite-lived brands in fiscal 2023.
Interest Expense, Net
Interest expense, net was $35.3 million during the six months ended September 30, 2023 versus $32.3 million during the six months ended September 30, 2022. The average indebtedness decreased to $1.3 billion during the six months ended September 30, 2023 from $1.5 billion during the six months ended September 30, 2022. The average cost of borrowing increased to 5.4% for the six months ended September 30, 2023 compared to 4.3% for the six months ended September 30, 2022.
Income Taxes
The provision for income taxes during the six months ended September 30, 2023 was $32.3 million versus $31.2 million during the six months ended September 30, 2022. The effective tax rate during the six months ended September 30, 2023 was 23.2% versus 22.7% during the six months ended September 30, 2022. The increase in the effective tax rate for the six months ended September 30, 2023 compared to the six months ended September 30, 2022 was due to the impact of discrete items primarily pertaining to state tax rate legislative changes and stock-based compensation.
Liquidity and Capital Resources
Liquidity
Our primary source of cash comes from our cash flow from operations. In the past, we have supplemented this source of cash with various debt facilities, primarily in connection with acquisitions. We have financed our operations, and expect to continue to finance our operations for the next twelve months and the foreseeable future, with a combination of funds generated from operations and borrowings. Our principal uses of cash are for operating expenses, debt service, share repurchases, capital expenditures, and acquisitions. Based on our current levels of operations and anticipated growth, excluding acquisitions, we believe that our cash generated from operations and our existing credit facilities will be adequate to finance our working capital and capital expenditures through the next twelve months. See "Economic Environment" above.
As of September 30, 2023, we had cash and cash equivalents of $60.1 million, an increase of $1.6 million from March 31, 2023. The following table summarizes the change:
(In thousands)
| Cash provided by (used in): | Six Months Ended September 30, 2023 | 2022 | $ Change |
|---|---|---|---|
| Operating Activities | $110,547 | $115,787 | $(5,240) |
| Investing Activities | (611) | (3,423) | 2,812 |
| Financing Activities | (107,728) | (95,330) | (12,398) |
| Effects of exchange rate changes on cash and cash equivalents | (630) | (1,777) | 1,147 |
| Net change in cash and cash equivalents | $1,578 | $15,257 | $(13,679) |
Operating Activities
Net cash provided by operating activities was $110.5 million for the six months ended September 30, 2023, compared to $115.8 million for the six months ended September 30, 2022. The $5.2 million decrease was primarily due to increased working capital, partly offset by an increase in net income before non-cash items.
Investing Activities
Net cash used in investing activities was $0.6 million for the six months ended September 30, 2023, compared to $3.4 million for the six months ended September 30, 2022. The change was primarily due to proceeds we received from a short term loan repayment, partly offset by an increase in capital expenditures.
-27-
Financing Activities
Net cash used in financing activities was $107.7 million for the six months ended September 30, 2023, compared to $95.3 million for the six months ended September 30, 2022. The $12.4 million increase was primarily due to lower net borrowings of $45.0 million compared to the prior year six month period, partly offset by a decrease in the repurchase of shares of our common stock in conjunction with our share repurchase program of $25.0 million and an increase in the proceeds from exercise of stock options of $7.7 million in the six months ended September 30, 2023.
Capital Resources
As of September 30, 2023, we had an aggregate of $1.3 billion of outstanding indebtedness, which consisted of the following:
- $400.0 million of 5.125% 2019 senior unsecured notes, which mature on January 15, 2028 (the "2019 Senior Notes");
- $600.0 million of 3.750% 2021 senior unsecured notes, which mature on April 1, 2031 (the "2021 Senior Notes"); and
- $275.0 million of borrowings under the Term B-5 Loans under our term loan originally entered into on January 31, 2012 (the "2012 Term Loan”) due July 1, 2028.
As of September 30, 2023, we had no outstanding balance on our asset-based revolving credit facility originally entered into on January 31, 2012 (the "2012 ABL Revolver”) and a borrowing capacity of $171.2 million.
Since we have made optional payments that exceed all of our required quarterly payments, we will not be required to make another payment on the 2012 Term Loan until maturity.
Maturities:
(In thousands)
| Year Ending March 31, | Amount |
|---|---|
| 2024 (remaining six months ending March 31, 2024) | $— |
| 2025 | — |
| 2026 | — |
| 2027 | — |
| 2028 | 400,000 |
| Thereafter | 875,000 |
| $1,275,000 |
Covenants:
Our debt facilities contain various financial covenants, including provisions that require us to maintain certain leverage, interest coverage and fixed charge ratios. The credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2021 Senior Notes and 2019 Senior Notes contain provisions that accelerate our indebtedness on certain changes in control and restrict us from undertaking specified corporate actions, including asset dispositions, acquisitions, payments of dividends and other specified payments, repurchasing our equity securities in the public markets, incurrence of indebtedness, creation of liens, making loans and investments and transactions with affiliates. Specifically, we must:
- Have a leverage ratio of less than 6.50 to 1.0 for the quarter ended September 30, 2023 and thereafter (defined as, with certain adjustments, the ratio of our consolidated total net debt as of the last day of the fiscal quarter to our trailing twelve month consolidated net income before interest, taxes, depreciation, amortization, non-cash charges and certain other items (“EBITDA”));
- Have an interest coverage ratio of greater than 2.25 to 1.0 for the quarter ended September 30, 2023 and thereafter (defined as, with certain adjustments, the ratio of our consolidated EBITDA to our trailing twelve month consolidated cash interest expense); and
- Have a fixed charge ratio of greater than 1.0 to 1.0 for the quarter ended September 30, 2023 (defined as, with certain adjustments, the ratio of our consolidated EBITDA minus capital expenditures to our trailing twelve month consolidated interest paid, taxes paid and other specified payments). Our fixed charge requirement remains level throughout the term of the debt facilities.
-28-
At September 30, 2023, we were in compliance with the applicable financial and restrictive covenants under the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2021 Senior Notes and the 2019 Senior Notes. Management anticipates that in the normal course of operations, we will be in compliance with the financial and restrictive covenants during the next twelve months.
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. A summary of our critical accounting policies is presented in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. There were no material changes to our critical accounting policies during the six months ended September 30, 2023.
Recent Accounting Pronouncements
A description of recently adopted accounting pronouncements is included in the notes to the unaudited Condensed Consolidated Financial Statements in Part I, Item I, Note 1 of this Quarterly Report on Form 10-Q.
-29-
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operations. The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the “safe harbor” provisions of the PSLRA.
Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required under federal securities laws and the rules and regulations of the SEC, we do not intend to update any forward-looking statements to reflect events or circumstances arising after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements included in this Quarterly Report on Form 10-Q or that may be made elsewhere from time to time by, or on behalf of, us. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.
These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “anticipate,” “expect,” “estimate,” "plan," “project,” "intend," "strategy," "goal," "objective," "future," "seek," "may," "might," "should," "would," "will," "will be," or other similar words and phrases. Forward-looking statements are based on current expectations and assumptions that are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation:
- Price increases for raw materials, labor, energy and transportation costs, and for other input costs;
- Disruptions of supply of sourced goods or components;
- The impact of geopolitical events and severe illness outbreaks on global economic conditions, consumer demand, retailer product availability, and business operations including manufacturing, supply chain and distribution;
- The high level of competition in our industry and markets;
- The level of success of new product introductions, line extensions, increased spending on advertising and marketing support, and other new sales and marketing strategies;
- Our dependence on a limited number of customers for a large portion of our sales;
- Our inability to successfully identify, negotiate, complete and integrate suitable acquisition candidates and to obtain necessary financing;
- Changes by retailers in inventory management practices, delivery requirements, and demands for marketing and promotional spending in order to retain or increase shelf space or online share;
- Our inability to grow our international sales;
- General economic conditions and incidence levels affecting sales of our products and their respective markets;
- Financial factors, such as increases in interest rates and currency exchange rate fluctuations;
- Changing consumer trends, additional store brand or branded competition, accelerating shifts to online shopping or pricing pressures;
- Our dependence on third-party manufacturers to produce many of the products we sell and our ability to transfer production to our own facilities or other third-party suppliers;
- Our dependence on third-party logistics providers to distribute our products to customers;
- Disruptions in our distribution center or manufacturing facility;
- Potential changes in export/import and trade laws, regulations and policies including any increased trade restrictions or tariffs;
- Acquisitions, dispositions or other strategic transactions diverting managerial resources and creating additional liabilities;
- Actions of government agencies in connection with our manufacturing plant, products, advertising or regulatory matters;
- Product liability claims, product recalls and related negative publicity;
- Our inability to protect our intellectual property rights;
- Our dependence on third parties for intellectual property relating to some of the products we sell;
- Our inability to protect our information technology systems from threats or disruptions;
- Our dependence on third-party information technology service providers and their ability to protect against security threats and disruptions;
- Our assets being comprised virtually entirely of goodwill and intangibles and possible changes in their value based on adverse operating results and/or changes in the discount rate used to value our brands;
- Our dependence on key personnel;
- The costs associated with any claims in litigation or arbitration and any adverse judgments rendered in such litigation or arbitration;
- Our level of indebtedness and possible inability to service our debt or to obtain additional financing;
-30-
- The restrictions imposed by our financing agreements on our operations; and
- Changes in federal, state and other geographic tax laws.
For more information, see Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.
-31-
Market risk
As filed, 1,807 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Interest Rate Risk
We are exposed to changes in interest rates because our 2012 Term Loan and 2012 ABL Revolver are variable rate debt. At September 30, 2023, approximately $275.0 million of our debt carries a variable rate of interest.
Holding other variables constant, including levels of indebtedness, a 1.0% increase in interest rates on our variable rate debt would have an adverse impact on pre-tax earnings and cash flows for the three and six months ended September 30, 2023 of approximately $0.8 million and $1.6 million, respectively.
Foreign Currency Exchange Rate Risk
During the three and six months ended September 30, 2023, approximately 13.5% and 12.7%, respectively, of our gross revenues were denominated in currencies other than the U.S. Dollar. During the three and six months ended September 30, 2022, approximately 13.1% and 13.3%, respectively, of our gross revenues were denominated in currencies other than the U.S. Dollar. As such, we are exposed to transactions that are sensitive to foreign currency exchange rates. These transactions are primarily with respect to the Canadian and Australian Dollars.
We performed a sensitivity analysis with respect to exchange rates for the three and six months ended September 30, 2023 and 2022. Holding all other variables constant, and assuming a hypothetical 10.0% adverse change in foreign currency exchange rates, this analysis resulted in a less than 5.0% impact on pre-tax income of approximately $2.4 million for the three months ended September 30, 2023 and approximately $4.1 million for the six months ended September 30, 2023. It represented a less than 5.0% impact on pre-tax income of approximately $2.6 million for the three months ended September 30, 2022 and $4.8 million for the six months ended September 30, 2022.
Controls and procedures
As filed, 1,322 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a–15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of September 30, 2023. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2023, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 1,154 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should carefully consider the risk factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended March 31, 2023, which could materially affect our business, financial condition or results of operations. The risk factors described in our Annual Report on Form 10-K have not materially changed in the period covered by this Quarterly Report on Form 10-Q, but such risks are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations.
Our quarterly operating results and revenues may fluctuate as a result of any of these or other factors. Accordingly, results for any one quarter are not necessarily indicative of results to be expected for any other quarter or for any year, and revenues for
-32- any particular future period may decrease. In the future, operating results may fall below the expectations of securities analysts and investors. In that event, the market price of our outstanding securities could be adversely impacted.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $286.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-04-01 to 2023-09-30 | $565.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $126.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-04-01 to 2023-09-30 | $250.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-07-01 to 2023-09-30 | $160.0m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-04-01 to 2023-09-30 | $314.7m | us-gaap:GrossProfit |
| Operating income | 3 months2023-07-01 to 2023-09-30 | $88.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-04-01 to 2023-09-30 | $173.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-07-01 to 2023-09-30 | $16.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-04-01 to 2023-09-30 | $32.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | $53.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-04-01 to 2023-09-30 | $106.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | $1.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-04-01 to 2023-09-30 | $2.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | $1.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-04-01 to 2023-09-30 | $2.15 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 50,081,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-04-01 to 2023-09-30 | 50,138,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-04-01 to 2023-09-30 | $110.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-04-01 to 2023-09-30 | $4.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2023-04-01 to 2023-09-30 | $25.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-09-30 | $60.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $388.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $3.33bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $129.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $1.80bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-09-30 | $1.27bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-09-30 | $1.54bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001295947-23-000034. Last ingested by Listed: Nov 5, 2026, 11:26 ET. Listed shows no prices and gives no investment advice.